McKinsey agrees to $78 million settlement | CityNews Calgary
Consulting agency McKinsey and Co. has agreed to pay $78 million to settle claims from insurers and well being care funds that its work with drug firms helped gas an opioid dependancy disaster.
The settlement was revealed late Friday in paperwork filed in federal courtroom in San Francisco. The settlement should nonetheless be accepted by a decide.
Under the settlement, McKinsey would set up a fund to reimburse insurers, personal profit plans and others for some or all of their prescription opioid prices.
The insurers argued that McKinsey labored with Purdue Pharma – the maker of OxyContin – to create and make use of aggressive advertising and gross sales ways to beat medical doctors’ reservations concerning the extremely addictive medicine. Insurers mentioned that compelled them to pay for prescription opioids quite than safer, non-addictive and lower-cost medicine, together with over-the-counter ache remedy. They additionally needed to pay for the opioid dependancy therapy that adopted.
Related Video:
From 1999 to 2021, almost 280,000 folks within the U.S. died from overdoses of prescription opioids, in response to the U.S. Centers for Disease Control. Insurers argued that McKinsey labored with Purdue Pharma even after the extent of the opioid disaster was obvious.
The settlement is the most recent in a years-long effort to carry McKinsey accountable for its position within the opioid epidemic. In February 2021, the corporate agreed to pay almost $600 million to U.S. states, the District of Columbia and 5 U.S. territories. In September, the corporate introduced a separate, $230 million settlement settlement with faculty districts and native governments.
Asked for remark Saturday, McKinsey referred to an announcement it launched in September.
“As we have stated previously, we continue to believe that our past work was lawful and deny allegations to the contrary,” the corporate mentioned, including that it reached a settlement to keep away from protracted litigation.
McKinsey mentioned it stopped advising shoppers on any opioid-related business in 2019.
